Johnson & Johnson is the latest pharmaceutical company to agree to U.S. President Donald Trump’s directive to lower the price of medicine for Americans. The company said on Jan. 9, 2026 that it would enable U.S. patients to access drugs at prices comparable to other developed nations.

That strategy, known as most-favored-nation (MFN) pricing, is one the White House requested of 17 major pharma companies in summer 2025. Johnson & Johnson’s agreement leaves only two of the 17, AbbVie and Regeneron, that have not yet cut a price deal with the Trump administration.

J&J Celebrates Price Agreement

“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans.”

As part of the agreement, Johnson & Johnson will be participating in the TrumpRx.gov discount drug marketplace. Certain Johnson & Johnson products also receive an exemption from pharmaceutical tariffs.

More Johnson & Johnson News

Also on Jan. 9, Johnson & Johnson announced two new manufacturing facilities in the U.S. These will be a next-generation cell therapy site in Pennsylvania, and a state-of-the-art drug product facility in North Carolina.

The company additionally said work is progressing on a $2 billion biologics manufacturing facility in North Carolina.

Other Companies to Reach MFN Pacts

In December 2025, nine pharma companies—more than half of those targeted by Trump—agreed to the MFN terms. These were Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.

AstraZeneca, EMD Serono, Eli Lilly, Novo Nordisk, and Pfizer reached agreements earlier in 2025.